<DOC>
	<DOCNO>NCT02478125</DOCNO>
	<brief_summary>Hypothesis : Treatment Burixafor hydrobromide effectively mobilize metastatic prostate cancer ( PCa ) cell ( i.e . disseminate tumor cell ; DTCs ) blood bone marrow . It demonstrate prostate cancer cell mobilize bone marrow mouse utilize anti-CXCR4 strategy ; make susceptible chemotherapy .</brief_summary>
	<brief_title>Pilot Study Mobilization Treatment Disseminated Tumor Cells Men With Metastatic Prostate Cancer</brief_title>
	<detailed_description>This open label , multiple site , pilot study . Hypothesis : Treatment Burixafor hydrobromide effectively mobilize metastatic prostate cancer ( PCa ) cell ( i.e . disseminate tumor cell ; DTCs ) blood bone marrow . In preclinical model , bone marrow niche engage cell resistant therapy compare soft tissue site . It demonstrate prostate cancer cell mobilize bone marrow mouse utilize anti-CXCR4 strategy ; make susceptible chemotherapy . Currently , anti-CXCR4 agent plerixafor FDA approve give 4 consecutive day order mobilize hematopoietic stem cell ( HSCs ) . Burixafor hydrobromide potent anti-CXCR4 agent clinical trial . Burixafor hydrobromide , alone combination G-CSF , currently Phase II test use hematopoetic stem cell ( HSC ) mobilization agent . When Burixafor hydrobromide give intravenously ( IV ) alone dose 3.14 mg/kg show result 7.8 fold mean increase peripheral blood CD34+ ( HSC marker ) cell 6-hours post-infusion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Have sign inform consent document indicate subject understands purpose procedure require study willing participate study 2 . Be willing/able adhere prohibition restriction specify protocol 3 . Male age 18 year 4 . Eastern cooperative group ( ECOG ) performance status ≤2 5 . Documented histologically confirm adenocarcinoma prostate 6 . Metastatic prostate cancer bone document positive bone scan image 7 . Patient must eligible chemotherapy docetaxel 8 . Patient must evidence castrate resistant prostate cancer evidence confirm rise PSA ( per Prostate Cancer Working Group 2 [ PCWG2 ] criterion ) castrate serum testosterone level ( i.e . ≤ 50 mg/dL ) . 1 . Have know allergy , hypersensitivity , intolerance docetaxel dexamethasone excipients 2 . Prior pelvic radiation ( e.g . external beam , brachytherapy , etc ) , opinion investigator , may lead decrease bone marrow cellularity marrow sample obtain pelvic bone marrow biopsy 3 . Ongoing systemic therapy ( GnRH agonist/antagonist ) prostate cancer include , limited : 1 . CYP17 inhibitor ( e.g . ketoconazole , abiraterone ) 2 . Antiandrogens ( e.g . bicalutamide , nilutamide ) 3 . Second generation antiandrogens ( e.g . enzalutamide ) 4 . Immunotherapy ( e.g . sipuleucelT , ipilimumab ) 5 . Chemotherapy ( e.g . docetaxel , cabazitaxel ) 4 . Prior radiopharmaceutical therapy ( e.g . radium223 , strontium89 , samarium153 , etc ) within past year 5 . Have condition , opinion investigator , would compromise wellbeing subject study prevent subject meeting performing study requirement 6 . Active infection medical condition would make corticosteroid ( i.e . dexamethasone ) use contraindicate 7 . Uncontrolled hypertension ( systolic BP ≥ 160 mmHg diastolic BP ≥ 95 mmHg ) Patients history hypertension allow provide blood pressure control antihypertensive treatment 8 . Severe hepatic impairment ( ChildPugh Class C ) 9 . History pituitary adrenal dysfunction ( note : use daily steroid exclude someone participate study ) 10 . Have poorly control diabetes ( HgB A1C ≥ 8 % ) 11 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>metastatic castrate resistant prostate cancer</keyword>
</DOC>